NEW YORK (Reuters Health)—U.K. experts propose evidence-based management strategies for rheumatology patients on immunosuppressive therapy, including delaying/postponing rituximab, as appropriate. “The aim of this viewpoint article is to outline the existing data on the effect of anti-rheumatic therapy on vaccine responses in patients with inflammatory arthritis and to formulate a possible pragmatic strategy for the…
FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD
Subcutaneous tocilizumab is the first biologic agent approved by the FDA treat patients with systemic sclerosis-associated interstitial lung disease.
Non-Invasive Vagus Nerve Stimulation Tolerated, Effective for Rheumatoid Arthritis
(Reuters Health)—Non-invasive vagus nerve stimulation is safe and effective as an intervention for rheumatoid arthritis (RA), a small proof-of-concept study suggests. The study enrolled 35 patients with active RA and an inadequate response to therapy with disease-modifying anti-rheumatic drugs (DMARDs). All DMARDS were discontinued four weeks prior to the trial. For the study, all participants…
ACR Endorses Woodcock for FDA Commissioner, Begins Relationship Building with New Administration Leaders
With the approval of its Board of Directors, the ACR sent a letter to President Biden and newly minted Secretary of Health & Human Services Xavier Becerra, strongly supporting Janet Woodcock, MD, to be nominated as the FDA’s permanent commissioner. The ACR also congratulated Secretary Becerra upon his confirmation.
When Switching Patients to Biosimilars, Communication & Expert Nurses Reduce the Nocebo Effect
In a recent study, researchers designed an intervention centered on communication and led by nurses to address discontinuation rates among patients who had switched to a biosimilar. The nurses’ insight and experience reduced the nocebo effect during the intervention, which had an 84% retention rate for patients taking a biosimilar after one year.
Louisa Ziglar, MD, FACR: ‘Everyone Can Be an Advocate’
When it comes to advocating for rheumatology, it’s never too early or late in your career to begin, and no effort is too small to have an impact, says Dr. Ziglar, a private practitioner and member of the Government Affairs Committee.
Improving Demographic Representation & Equity in Rheumatology Research
A better understanding of knowledge gaps and increased engagement of underrepresented communities are needed to diversify rheumatology patient data in clinical datasets, registries and randomized clinical trials.
COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy
State-level wins that ensure immunosuppressed patients can access COVID-19 vaccination show the power of coordinated efforts by volunteer leaders, staff and members to translate the ACR’s work into actionable public policy recommendations, then amplify those messages through member engagement.
Pediatric Rheumatology Workforce Challenges in the Dakotas
Pediatric rheumatologists are few and far between in rural America. Financial incentives, such as loan repayment, may help draw more providers to the subspecialty and the underserved regions of the U.S.
Extreme & Uncontrollable Circumstances Application for 2020 Merit-Based Incentive Payment System Reopened
The Centers for Medicare & Medicaid Services reopened the Extreme & Uncontrollable Circumstances application and indicated they will automatically apply the policy to individuals who do not submit data for 2020 Merit-based Incentive Payment System.
- « Previous Page
- 1
- …
- 73
- 74
- 75
- 76
- 77
- …
- 325
- Next Page »